MAY 15 2026
Genentech — Tecentriq (atezolizumab) $RHHBY
for muscle-invasive bladder cancer
FDA approved Genentech's Tecentriq for adjuvant treatment of muscle-invasive bladder cancer using ctDNA-guided therapy.
About
Muscle-invasive bladder cancer is an aggressive disease where abnormal cells form a tumor that can spread beyond the bladder and damage other organs. Tecentriq (atezolizumab) is an antibody that blocks a protein used by tumors to hide from the body's immune defenses. By unmasking the cancer cells, this drug could help the immune system find and attack them, potentially preventing the disease from returning after surgery.
Pivotal trial
Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large trials for new treatments
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Tecentriq
- Tecentriq Approved for Muscle-Invasive Bladder Cancer - Specialty Pharmacy Continuum
- FDA grants priority review for Roche’s Tecentriq combo sBLA - Pharmaceutical Technology
- FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer - GlobeNewswire
- Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer - Yahoo Finance
- FDA accepts Roche’s Tecentriq sBLA for priority review - The Pharma Letter